131 related articles for article (PubMed ID: 29115401)
1. Inhibitors targeting the SUMOylation pathway: A patent review 2012‑2015 (Review).
Zhou Y; Ji C; Cao M; Guo M; Huang W; Ni W; Meng L; Yang H; Wei JF
Int J Mol Med; 2018 Jan; 41(1):3-12. PubMed ID: 29115401
[TBL] [Abstract][Full Text] [Related]
2. Development of a high-throughput screening assay for inhibitors of small ubiquitin-like modifier proteases.
Yang W; Wang L; Paschen W
J Biomol Screen; 2013 Jun; 18(5):621-8. PubMed ID: 23470489
[TBL] [Abstract][Full Text] [Related]
3. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
Citro S; Chiocca S
Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.
Yang Y; Xia Z; Wang X; Zhao X; Sheng Z; Ye Y; He G; Zhou L; Zhu H; Xu N; Liang S
Mol Pharmacol; 2018 Aug; 94(2):885-894. PubMed ID: 29784649
[TBL] [Abstract][Full Text] [Related]
5. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
6. Generation of specific inhibitors of SUMO-1- and SUMO-2/3-mediated protein-protein interactions using Affimer (Adhiron) technology.
Hughes DJ; Tiede C; Penswick N; Tang AA; Trinh CH; Mandal U; Zajac KZ; Gaule T; Howell G; Edwards TA; Duan J; Feyfant E; McPherson MJ; Tomlinson DC; Whitehouse A
Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138295
[TBL] [Abstract][Full Text] [Related]
7. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
8. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.
He X; Riceberg J; Soucy T; Koenig E; Minissale J; Gallery M; Bernard H; Yang X; Liao H; Rabino C; Shah P; Xega K; Yan ZH; Sintchak M; Bradley J; Xu H; Duffey M; England D; Mizutani H; Hu Z; Guo J; Chau R; Dick LR; Brownell JE; Newcomb J; Langston S; Lightcap ES; Bence N; Pulukuri SM
Nat Chem Biol; 2017 Nov; 13(11):1164-1171. PubMed ID: 28892090
[TBL] [Abstract][Full Text] [Related]
9. SENP3 regulates the global protein turnover and the Sp1 level via antagonizing SUMO2/3-targeted ubiquitination and degradation.
Wang M; Sang J; Ren Y; Liu K; Liu X; Zhang J; Wang H; Wang J; Orian A; Yang J; Yi J
Protein Cell; 2016 Jan; 7(1):63-77. PubMed ID: 26511642
[TBL] [Abstract][Full Text] [Related]
10. Identification of new SUMO activating enzyme 1 inhibitors using virtual screening and scaffold hopping.
Kumar A; Ito A; Hirohama M; Yoshida M; Zhang KY
Bioorg Med Chem Lett; 2016 Feb; 26(4):1218-23. PubMed ID: 26810265
[TBL] [Abstract][Full Text] [Related]
11. The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis C; Hassan Z; Schick M; Keller U; Schneider G
Br J Cancer; 2021 Feb; 124(3):531-538. PubMed ID: 33071285
[TBL] [Abstract][Full Text] [Related]
12. SUMO2/3 modification of activating transcription factor 5 (ATF5) controls its dynamic translocation at the centrosome.
Yuan Y; Gaither K; Kim E; Liu E; Hu M; Lengel K; Qian D; Xu Y; Wang B; Knipprath H; Liu DX
J Biol Chem; 2018 Feb; 293(8):2939-2948. PubMed ID: 29326161
[TBL] [Abstract][Full Text] [Related]
13. A Fluorescent In Vitro Assay to Investigate Paralog-Specific SUMO Conjugation.
Eisenhardt N; Chaugule VK; Pichler A
Methods Mol Biol; 2016; 1475():67-78. PubMed ID: 27631798
[TBL] [Abstract][Full Text] [Related]
14. Targeting SUMO Signaling to Wrestle Cancer.
Kroonen JS; Vertegaal ACO
Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics Tools for Exploring the SUMO Gene Network.
Castro PH; Santos MÂ; Magalhães AP; Tavares RM; Azevedo H
Methods Mol Biol; 2016; 1450():285-301. PubMed ID: 27424763
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 2',3',4'-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation.
Kim YS; Keyser SG; Schneekloth JS
Bioorg Med Chem Lett; 2014 Feb; 24(4):1094-7. PubMed ID: 24468414
[TBL] [Abstract][Full Text] [Related]
17. SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Ahner A; Frizzell RA
Curr Drug Targets; 2015; 16(9):965-75. PubMed ID: 26028049
[TBL] [Abstract][Full Text] [Related]
18. Targeting the SUMO pathway for neuroprotection in brain ischaemia.
Yang W; Sheng H; Wang H
Stroke Vasc Neurol; 2016 Sep; 1(3):101-107. PubMed ID: 28959470
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Histone Deacetylases Sumoylation by Immunoprecipitation Techniques.
Wagner T; Godmann M; Heinzel T
Methods Mol Biol; 2017; 1510():339-351. PubMed ID: 27761833
[TBL] [Abstract][Full Text] [Related]
20. PHD3-SUMO conjugation represses HIF1 transcriptional activity independently of PHD3 catalytic activity.
Núñez-O'Mara A; Gerpe-Pita A; Pozo S; Carlevaris O; Urzelai B; Lopitz-Otsoa F; Rodríguez MS; Berra E
J Cell Sci; 2015 Jan; 128(1):40-9. PubMed ID: 25380826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
